Surprise! PDUFA Fees Dropping In FY 2021
Executive Summary
A more than 2% drop for NDAs and BLAs in FY 2021, while program fees will increase more than 3%.
You may also be interested in...
Priority Review Voucher Fee Decreases For FY 2021 May Reflect US FDA Personnel Changes
In part because assessment costs plummeted in FY 2019, the FY 2021 fee to redeem a priority review voucher will be 37% less than the previous year.
PDUFA Application Fee Nears $3m Threshold In FY 2020
The US FDA fee for a new drug or biologics license application requiring clinical data will jump to $2.94m in October.
Gene Therapy: Pediatric Development Could Start Sooner Than Sponsors Think – FDA OTP Director
Nicole Verdun said children could participate in gene therapy clinical trials earlier if the necessary controls are in place.